CORDIS
EU research results

CORDIS

English EN

Exploiting Gram-negative cell division targets in the test tube to obtain anti-microbial compounds

Project information

Grant agreement ID: 223431

Status

Closed project

  • Start date

    1 March 2009

  • End date

    31 August 2013

Funded under:

FP7-HEALTH

  • Overall budget:

    € 8 149 653,80

  • EU contribution

    € 5 956 086

Coordinated by:

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Spain

Objective

The DIVINOCELL project will identify novel Gram-negative targets by exploiting the components of the divisome, their activities and interactions. It will also design selective assays for screening and will obtain a new class of antimicrobials: compounds to block bacterial division. New medicines to attack Gram-negative pathogens will decrease the burden of infectious disease and have a highly beneficial social and economic impact in Europe and beyond. Cell division is an essential and still underexploited process with excellent properties to yield new inhibitors to attack infection by blocking the proliferation of pathogens. Inhibitors directed against bacterial division targets, that are not present in eukaryotic cells, will be both effective and innocuous to humans and animals. In addition, as many of their structures will be based on interaction domains and synthetic scaffolds, they will generate resistance at levels lower than the present antibiotics. DIVINOCELL will apply existing and new knowledge on the molecular biology of Gram-negative cell division as well as novel analytical (nanodiscs), bioinformatic (molecular dynamics), structural (membrane protein crystals) and imaging (lanthanide staining) tools to exploit in the test tube the structures and interactions of targets in the divisome and the septum. DIVINOCELL will develop potent systematic screening assays and will use them to select compounds specifically tailored to inhibit the division of Gram-negatives (not precluding broad spectrum ones). Secondary activity and cell assays, based on the properties of bacterial division, will be generated to validate hits and advance them to leads. The medicinal properties of selected leads will be improved. The translational steps of the project will be developed by 4 SMEs in close collaboration with the 8 academic partners having well-proven expertise in molecular microbiology, protein chemistry, structural biology, biophysics, imaging and bioinformatics.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Address

Calle Serrano 117
28006 Madrid

Spain

Activity type

Research Organisations

EU Contribution

€ 1 231 767

Administrative Contact

Alberto Sereno Alvarez (Mr.)

Participants (11)

BIOMOL-INFORMATICS SL

Spain

EU Contribution

€ 409 100

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 346 630

EVOLVA BIOTECH A/S

Denmark

EU Contribution

€ 673 160

MEDICAL RESEARCH COUNCIL

United Kingdom

EU Contribution

€ 522 039

DEMURIS LIMITED

United Kingdom

EU Contribution

€ 489 700

UNIVERSIDAD DE CHILE

Chile

EU Contribution

€ 153 201

UNIVERSITY OF NEWCASTLE UPON TYNE

United Kingdom

EU Contribution

€ 722 144

UNIVERSITEIT VAN AMSTERDAM

Netherlands

EU Contribution

€ 627 501

VICHEM CHEMIE KUTATO KFT

Hungary

EU Contribution

€ 333 940

VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG

Netherlands

STICHTING VU

Netherlands

EU Contribution

€ 446 904

Project information

Grant agreement ID: 223431

Status

Closed project

  • Start date

    1 March 2009

  • End date

    31 August 2013

Funded under:

FP7-HEALTH

  • Overall budget:

    € 8 149 653,80

  • EU contribution

    € 5 956 086

Coordinated by:

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Spain